Article

Ra-223 Displays Efficacy, Safety in mCRPC With Bone Metastases

Author(s):

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Prostate Cancer

Prostate Cancer

Radium-223 (Xofigo) demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer (mCRPC) that metastasized to the bones, according to findings from a real-world study (NCT04232761) presented at the 2023 Genitourinary Cancers Symposium.

Although researchers assessed treatment with radium-223 in the first-, second-, and third-line settings, patients treated in the first-line setting had fewer treatment-related adverse events and higher rates of treatment completion with 6 injections.

A total of 224 patients were included in the multicenter observational trial in Taiwan, of whom 97 were in the safety analysis set. Of these patients, 22 received radium-223 as first-line treatment, 42 as second-line treatment, and 33 as third-line treatment.

Previous lines of therapy included abiraterone and/or enzalutamide (Xtandi) (72.2%; n = 70) as well as docetaxel (34%; n = 33).

Of note, 55% of patients received a full course (6 injections) of radium-223 injections, and 67% received 5 of the 6 injections. The most common reason for treatment discontinuation was disease progression (12%; n = 12).

In patients treated in the first-line setting, 36.4% experienced decreased PSA levels compared with 20% of patients in the second-line cohort and 14% in the third-line cohort. Total alkaline phosphatase levels decreased in 77% of patients in the first-line group, 82% in the second-line group and 60% in the third-line group, underscoring the enhanced efficacy of radium-223 as a front-line therapy, according to the researchers.

The most common reasons for treatment discontinuation of patients in this study were patient decision (9.3%), disease progression (12.4%), and adverse events (6.2%). In addition, 5% of patients in the second-line cohort and 12% of patients in the third-line cohort died before completing the injection course.

The most common treatment-related adverse events were hematological events (9.3%) and diarrhea (8.2%), bone pain (7.2%) and decreased appetite (7.2%).

The relatively low rate of treatment-related adverse events and lack of new safety concerns presented in this study demonstrates the safety of radium-223 under routine clinical practice in Taiwan treating bone metastases related to castration-resistant prostate cancer, according to the poster. A follow-up observation up to 2 years after initial injection is currently ongoing.

Reference

Pang ST, Huang CY, Huang CP, et al. Patient characteristics and safety of radium-223 dichloride in Taiwan: Analysis of real-world clinical practice. Presented at: 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023; San Francisco, CA. Abstract 119.

Related Videos
Atish D. Choudhury, MD, PhD
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Manali Kamdar, MD
Ibrahim Aldoss, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Anthony V. D'Amico, MD, PhD
Ana Christina Garrido-Castro, MD